Get the Stockscreener App
14.13
8.84%
-1.37
After Hours:
14.00
-0.13
-0.92%
Cogent Biosciences Inc stock is traded at $14.13, with a volume of 5.55M.
It is down -8.84% in the last 24 hours and down -10.34% over the past month.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
See More
Previous Close:
$15.50
Open:
$15.24
24h Volume:
5.55M
Relative Volume:
2.94
Market Cap:
$1.61B
Revenue:
-
Net Income/Loss:
$-284.08M
P/E Ratio:
-5.8307
EPS:
-2.4234
Net Cash Flow:
$-234.65M
1W Performance:
-12.18%
1M Performance:
-10.34%
6M Performance:
+140.72%
1Y Performance:
+19.04%
1-Day Range:
$13.98
$15.90
1-Week Range:
$13.98
$16.75
52-Week Range:
$3.72
$17.15
Cogent Biosciences Inc Stock (COGT) Company Profile
Name
Cogent Biosciences Inc
Sector
Industry
Phone
617-945-5576
Address
275 WYMAN STREET, WALTHAM
Compare COGT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
COGT
Cogent Biosciences Inc
|
14.13 | 2.17B | 0 | -284.08M | -234.65M | -2.4234 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.67 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
628.00 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.47 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
831.48 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.77 | 39.72B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cogent Biosciences Inc Stock (COGT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-16-25 | Initiated | Stifel | Hold |
| Sep-03-25 | Initiated | Raymond James | Strong Buy |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Dec-11-24 | Downgrade | Needham | Buy → Hold |
| Feb-26-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-08-24 | Initiated | Citigroup | Buy |
| Dec-11-23 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-08-23 | Initiated | JP Morgan | Overweight |
| Apr-28-23 | Initiated | Robert W. Baird | Outperform |
| Mar-27-23 | Resumed | H.C. Wainwright | Buy |
| Dec-14-22 | Initiated | Needham | Buy |
| Jun-28-22 | Initiated | Guggenheim | Buy |
| Oct-11-21 | Initiated | H.C. Wainwright | Buy |
| Jun-09-21 | Resumed | Jefferies | Buy |
| Dec-23-20 | Initiated | Piper Sandler | Overweight |
| Oct-14-20 | Initiated | Ladenburg Thalmann | Buy |
View All
Cogent Biosciences Inc Stock (COGT) Latest News
HC Wainwright & Co. Reiterates Buy Rating for Cogent Biosciences (COGT) | COGT Stock News - GuruFocus
Will Cogent Biosciences Inc. stock maintain dividend yield2025 Price Targets & Smart Allocation Stock Reports - newser.com
What MACD and RSI say about Cogent Biosciences Inc.Day Trade & Weekly Top Stock Performers List - newser.com
What earnings revisions data tells us about Cogent Biosciences Inc.July 2025 News Drivers & Reliable Volume Spike Alerts - newser.com
How Cogent Biosciences Inc. stock benefits from tech adoption2025 Volatility Report & Stock Portfolio Risk Control - newser.com
Cogent Biosciences Spends Big As Drug Hopes Build - Finimize
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2025 Financial Results - Investing News Network
Cogent Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
Cogent Biosciences (COGT): Anticipated Data Releases and Strategic Advancements - GuruFocus
Cogent Biosciences (COGT) Boosts Financial Position with Strong Cash Reserves - GuruFocus
Cogent Biosciences posts wider Q3 loss as costs rise - MarketScreener
Cogent Biosciences Announces Multiple Presentations at the 67th Annual American Society of Hematology (ASH) Meeting - The Manila Times
Cogent Biosciences (NASDAQ: COGT) expects Phase 3 PEAK Nov and APEX Dec readouts - Stock Titan
Cogent Bio (NASDAQ: COGT) to present NonAdvSM bezuclastinib, JAK2 V617F poster at ASH - Stock Titan
How Cogent Biosciences Inc. stock performs in high volatility marketsBear Alert & Momentum Based Trading Ideas - newser.com
Why Cogent Biosciences Inc. stock remains resilient2025 Volatility Report & Growth-Oriented Investment Plans - newser.com
Candlestick signals on Cogent Biosciences Inc. stock todayJuly 2025 Momentum & Reliable Intraday Trade Plans - newser.com
What high frequency data says about Cogent Biosciences Inc.2025 Major Catalysts & Weekly Chart Analysis and Trade Guides - newser.com
Cogent Biosciences Inc.’s volatility index tracking explained2025 Fundamental Recap & AI Driven Stock Price Forecasts - newser.com
Is Cogent Biosciences Inc. stock a buy before product launches2025 Institutional Moves & Weekly Setup with High ROI Potential - newser.com
Will Cogent Biosciences Inc. stock benefit from upcoming earnings reportsMarket Risk Analysis & Real-Time Stock Entry Alerts - newser.com
Earnings visualization tools for Cogent Biosciences Inc.Quarterly Market Summary & Precise Trade Entry Recommendations - newser.com
How strong is Cogent Biosciences Inc. stock revenue growthBear Alert & Community Trade Idea Sharing - newser.com
Published on: 2025-11-02 00:56:21 - newser.com
Cogent Biosciences, Inc. (COGT) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
Can Cogent Biosciences Inc. stock rebound after recent weaknessMarket Performance Report & Long-Term Capital Growth Ideas - newser.com
Using R and stats models for Cogent Biosciences Inc. forecasting2025 Short Interest & Long-Term Growth Portfolio Plans - newser.com
Momentum divergence signals in Cogent Biosciences Inc. chart2025 Market Overview & Technical Pattern Based Signals - newser.com
Emerald Mutual Fund Advisers Trust Invests $6.43 Million in Cogent Biosciences, Inc. $COGT - MarketBeat
Full technical analysis of Cogent Biosciences Inc. stockJuly 2025 Reactions & Free Safe Capital Growth Stock Tips - newser.com
Published on: 2025-10-31 00:39:25 - newser.com
Cogent Biosciences Inc Stock (COGT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.45%
0.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):